Search

everythinglearnresearchcommunity

for

Search:↓

The post discusses the experiences of individuals with diffuse hair thinning using finasteride, with many reporting no improvement or worsening conditions after 6 months. Various suggestions include persisting with the treatment, checking for underlying conditions, adding minoxidil for volume, adjusting dosage, and considering other potential causes like autoimmune responses and inflammation.

A poor diet high in sugar and insulin resistance may reduce the effectiveness of finasteride in treating hair loss. Improving diet could potentially enhance treatment results.

Finasteride can reduce DHT levels by about 60%, but its effectiveness varies, and some users experience side effects like cognitive issues. Combining finasteride with other treatments like dutasteride or minoxidil may enhance hair regrowth, but individual responses differ.

A 36-year-old started using finasteride (0.3-0.5mg daily), 5% minoxidil foam, and weekly dermarolling/dermapen treatments to address hair loss. They also began taking supplements for low ferritin and vitamin D, hoping to improve hair thickness and cover a bald spot.

A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

Topical finasteride may have higher systemic absorption and lower efficacy when using a Propylene Glycol/Ethanol formulation compared to the hydroxypropyl chitosan (HPCH) formulation. The safety profile of topical finasteride relies heavily on the HPCH formulation, and using standard solutions might lead to different pharmacokinetics.

The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.

A user's experience with a hair transplant, as well as the use of finasteride to maintain results.

The user has been using finasteride and minoxidil for 5 years to prevent hair loss and is considering adding dutasteride for regrowth or opting for a hair transplant. Suggestions include trying dutasteride, oral minoxidil, microneedling, and possibly a hair transplant for better results.

Haircafe is generally trusted for hair loss information, particularly for his evidence-based approach and recommendations of finasteride, dutasteride, and minoxidil. While some users appreciate his scientific focus and lack of product promotion, others criticize his dismissal of anecdotal evidence and certain biases.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

The user discusses using Follics FR5, FR10, and FR15, which combine Minoxidil, Adenosine, Procapil, Azelaic acid, and Procyanidin B2, to address hair loss. They have previously used Minoxidil, Finasteride, and Dutasteride with varying success.

A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.

User phoenixblue asked about hair fiber products like Toppik and if they cause hair loss by clogging pores. Replies suggested that Toppik is safe, but effectiveness varies; some users experienced no hair loss, while others had issues with color or sweating.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

User follows a hair loss protocol with topical finasteride, minoxidil, RU58841, stemoxydine, and microneedling. They plan to get a hair transplant at month 9 and ask for opinions on their progress.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks upcoming Fluridil group buys.

The user experienced temporary peach fuzz growth using a product with procapil and later tried minoxidil and finasteride without significant results. Their boyfriend has used minoxidil and finasteride consistently for over five years with sparse hair improvement.

The user shared a four-month hair growth progress using 1mg finasteride daily, 2.5mg oral minoxidil daily, and Hims thick fix shampoo every other day. Replies include comments on photo quality and lighting, a joke about the frequency of Hims product mentions, and the original poster humorously wishing for a Hims sponsorship.

A user shared their experience with Finasteride for hair loss, noting improvement but still some thinning. They plan to get a hair transplant to address remaining thin spots and strengthen their hairline.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.

The user maintained hair with finasteride for 4.5 years and noticed some progress with dutasteride after 6 months, experiencing reduced chest and facial hair. They did not use minoxidil and reported no side effects from either treatment.

The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.